CD33 and acute myeloid leukemia: BM analysis demonstrated high CD33+ AML engraftment in TCR1G4-treated mice (mean, 86.9% ± 5.3%), which was reduced to a mean of 0.5% ± 0.2% in TCRFLT3D/Y-treated mice, with a similar reduction in the spleen (Fig. 3c,d and Supplementary Table 4).